Enhancing core lab capabilities
Supporting growth, productivity, and innovation
Lab of the Future
Lab of the Future – Vision

Energized and inspired workforce focused on innovation and knowledge-based activities

Automated production for accuracy, efficiency, and minimal turnaround time variation

Differentiated products developed at speed

Environmentally responsible footprint
Lab of the Future – Strategy

World-class products & facilities

- Build best-in-class facilities, streamline real estate portfolio and lab costs
- Establish sites for development and future M&A
- Design scalable, environmentally responsible spaces

Forward-thinking people strategy

- Reignite our high-performance culture
- Leverage investment in modern facilities to enhance recruiting and retention
- Create career advancement opportunities and enhance workforce capabilities
- Increase integration between Myriad sites

Cutting-edge automated platform

- Unify software and hardware platforms
- Improve efficiency, standardize operations, faster assay development
- Enable high-throughput Next Generation Sequencing operations in new, expanded Salt Lake City facility

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com
Multifaceted program to fuel growth and productivity

Broad scope to comprehend all elements of our lab operations

**WORKSTREAMS**

- **ASSAY ENHANCEMENT**
  - New features for current products
- **INNOVATION**
  - New differentiated product offerings
- **REAL ESTATE**
  - Modernize & streamline real estate portfolio
- **SCALE FOR GROWTH**
  - Geographically align high-throughput assays
- **AUTOMATION**
  - Automated backbone for lab operations

**FOCUS AREAS**

- Advanced sequencing
  - MyChoice
  - Foresight
  - Prequel
  - Advance whole exome across the portfolio
- Develop new products
  - FirstGene
  - Liquid biopsy
  - MRD
- Build world-class labs
  - New Bay Area facility
  - New Salt Lake City facility
  - Mason renovation
- Move existing labs
  - Foresight/Prequel to Salt Lake City
  - Move existing Salt Lake labs to modern facilities

**KPI IMPACT**

- ✓ Lower COGS
- ✓ Improve ordering customer experience
- ✓ Increased volume
- ✓ Increased revenue
- ✓ Year-over-year growth
- ✓ Turnover, retention
- ✓ Improved (audit) quality
- ✓ Real estate footprint and rent reduction
- ✓ Lower (staffing) OpEx
- ✓ Lower (real estate) OpEx
- ✓ Lower COGS
- ✓ Lower COGS
- ✓ Improved (audit) quality
- ✓ Faster turn around times
Execution plan supported by significant investment and top talent

**NovaSeq Transitions**
- Q1: Prenatal products shift to advanced sequencing
- Q2: Transition Innovation operations to new South San Francisco facility
- Q3: Transition Prenatal production to Salt Lake City
- Q4: Transition Salt Lake City Research Park products to new campus

**FirstGene**
- Q4: New Prenatal combined test offering

**New Facility Construction**
- Q1: South San Francisco innovation campus construction
- Q2: Salt Lake production lab campus construction

**Shift Operations to New Facilities**
- Q1: Transition Prenatal production to Salt Lake City
- Q2: Transition Salt Lake City Research Park products to new campus

**Advanced Automation**
- Q1: Design and build first phases of automation
- Q2: Early phase Prenatal lab automation
- Q3: Fully automate Prenatal labs

**MRD**
- Q1: New Measurable Residual Disease detection offering

**Liquid Biopsy**
- Q4: Liquid Tumor profiling

**Whole Exome**
- Q4: Phased approach: RUO → LDT → CDx

---

$80M* investment in modern labs to deliver

$12M annual savings, plus rent reductions starting in 2025

* >85% of investment is estimated to be Capitalizable expense

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com